HC Wainwright Reduces Earnings Estimates for FibroGen

FibroGen, Inc (NASDAQ:FGEN) – Equities research analysts at HC Wainwright cut their FY2025 earnings estimates for FibroGen in a report released on Tuesday, November 11th. HC Wainwright analyst M. Keller now expects that the biopharmaceutical company will post earnings per share of ($12.08) for the year, down from their previous forecast of ($10.84). HC Wainwright has a “Buy” rating and a $43.00 price target on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for FibroGen’s Q4 2025 earnings at ($2.95) EPS and FY2026 earnings at ($6.51) EPS.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($1.61) EPS for the quarter, topping the consensus estimate of ($4.01) by $2.40. The firm had revenue of $1.08 million for the quarter, compared to the consensus estimate of $1.64 million.

Several other brokerages have also recently issued reports on FGEN. Wall Street Zen raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroGen in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $43.00.

FibroGen Trading Down 0.9%

FGEN traded down $0.09 on Thursday, hitting $9.05. 22,273 shares of the company’s stock were exchanged, compared to its average volume of 68,861. FibroGen has a fifty-two week low of $4.85 and a fifty-two week high of $21.94. The stock has a market cap of $36.58 million, a price-to-earnings ratio of -23.80 and a beta of 0.75. The firm has a 50-day moving average price of $11.30 and a 200-day moving average price of $9.06.

Institutional Investors Weigh In On FibroGen

Several large investors have recently modified their holdings of FGEN. Connective Capital Management LLC acquired a new stake in shares of FibroGen during the second quarter worth approximately $80,000. HighTower Advisors LLC lifted its holdings in shares of FibroGen by 292.8% during the 1st quarter. HighTower Advisors LLC now owns 404,488 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 301,500 shares during the period. Vanguard Group Inc. raised its holdings in shares of FibroGen by 3.5% in the 3rd quarter. Vanguard Group Inc. now owns 184,244 shares of the biopharmaceutical company’s stock worth $2,257,000 after buying an additional 6,204 shares in the last quarter. Finally, Armistice Capital LLC grew its holdings in shares of FibroGen by 25.0% in the 1st quarter. Armistice Capital LLC now owns 8,500,000 shares of the biopharmaceutical company’s stock worth $2,634,000 after purchasing an additional 1,700,000 shares during the last quarter. 72.71% of the stock is owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.